XML 57 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1
Insider Trading Arrangements
 3 Months Ended 12 Months Ended
Dec. 31, 2024
shares
Dec. 31, 2024
shares
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
The following table describes, for the fourth quarter of 2024, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a "non-Rule 10b5-1 trading arrangement" (as defined in Item 408(c) of Regulation S-K):
Name and TitleAction Taken (Date of Action)Type of Trading ArrangementNature of Trading ArrangementDuration of Trading Arrangement
Aggregate Number of Shares of Common Stock
Robert Abel Executive Vice President, Chief Scientific Officer, Platform
Adoption
(November 26, 2024)
Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares
Sale
Until December 31, 2025, or such earlier date upon which all transactions are completed or expire without execution
Up to 107,605 shares
Karen Akinsanya, President of R&D, Therapeutics
Adoption
(December 17, 2024)
Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares
Sale
Until December 31, 2025, or such earlier date upon which all transactions are completed or expire without execution
Up to 121,178 shares
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Robert Abel [Member]    
Trading Arrangements, by Individual    
Name Robert Abel  
Title Executive Vice President, Chief Scientific Officer, Platform  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date November 26, 2024  
Expiration Date December 31, 2025  
Arrangement Duration 400 days  
Aggregate Available 107,605 107,605
Karen Akinsanya [Member]    
Trading Arrangements, by Individual    
Name Karen Akinsanya  
Title President of R&D, Therapeutics  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date December 17, 2024  
Expiration Date December 31, 2025  
Arrangement Duration 379 days  
Aggregate Available 121,178 121,178